Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

Launched by UNIVERSITY OF AARHUS · Jun 16, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the benefits of using magnetic resonance imaging (MRI) alongside the standard computed tomography (CT) scans for patients with pancreatic cancer. The goal is to see if adding MRI can help doctors better decide if surgery is possible for patients with certain types of pancreatic tumors. The study is currently looking for participants, and anyone aged 18 or older who has pancreatic cancer that is considered locally resectable or borderline resectable might be eligible. The patients must not have any liver metastases (cancer spread to the liver) and should have a diagnosis based on their CT scans.

If you decide to participate, you will undergo both MRI and CT scans as part of the process. This additional imaging may provide more detailed information about your condition, which can help in planning your treatment. It’s important to note that participants cannot have had previous chemotherapy treatments that may have shrunk the tumor, nor can they have any serious health conditions that would prevent surgery. Also, those who cannot safely undergo an MRI due to certain medical reasons, like kidney issues or claustrophobia, are not eligible for this trial. Overall, this study aims to improve the way doctors evaluate pancreatic cancer and potentially increase the chances of successful surgery for patients.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
• • No liver metastases on CT
• • At least 18 years old and able to provide informed consent
• • Expected pancreatic ductal adenocarcinoma based on CT scan
• Exclusion criteria:
• • Metastatic disease
• • Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
• • Comorbidity rendering major surgery unfeasible (inoperable)
• • No informed consent
• • Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
• • Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
• • MRI with liver-specific contrast performed during standard workup.